According to the NCI website, ripretinib is an orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Check for active clinical trials using this agent. (NCI Thesaurus)

Patient information

Indikationen/Anwendungsmöglichkeiten gemäss NCI Website:

• Gastrointestinal stromal tumor that is advanced. It is used in adults whose cancer has been treated with at least three kinase inhibitors, including imatinib mesylate.
• Ripretinib is also being studied in the treatment of other types of cancer.

More Information in English:

Inxight: Drugs (NIH)

AdisInsight

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute

Wiki
Link to European Medicines Agency (EMEA)